Search research articles
Contact Us
Filters
Showing results (401-410 of 527) with videos related to
Page
of 53
Sort By:
Anti-Cancer Drugs
|
January 24, 2018
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
Chandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, et al.
The Oncologist
|
May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Molecular Cancer Therapeutics
|
March 16, 2013
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
Edward B Garon, Richard S Finn, Habib Hamidi, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis
Min Woo Lee, Steven S Raman, Nazanin H Asvadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
Angelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
The Breast Journal
|
August 27, 2019
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Karen A Gelmon, Massimo Cristofanilli, Hope S Rugo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Josep M Llovet, Amit G Singal, Augusto Villanueva, et al.
Liver Cancer
|
December 18, 2025
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Sohyun Hwang, Dong Jun Shin, Beodeul Kang, et al.
Human Pathology
|
November 14, 2018
IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury
Nicole K Andeen, J Ashley Jefferson, Shreeram Akilesh, et al.
Page
of 53
Search research articles
Search
Showing results (401-410 of 527) with videos related to
Sort By:
Page
of 53
Anti-Cancer Drugs
|
January 24, 2018
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
Chandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, et al.
The Oncologist
|
May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Molecular Cancer Therapeutics
|
March 16, 2013
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
Edward B Garon, Richard S Finn, Habib Hamidi, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis
Min Woo Lee, Steven S Raman, Nazanin H Asvadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
Angelo Di Leo, Henry L Gomez, Zeba Aziz, et al.
The Breast Journal
|
August 27, 2019
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Karen A Gelmon, Massimo Cristofanilli, Hope S Rugo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Josep M Llovet, Amit G Singal, Augusto Villanueva, et al.
Liver Cancer
|
December 18, 2025
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Sohyun Hwang, Dong Jun Shin, Beodeul Kang, et al.
Human Pathology
|
November 14, 2018
IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury
Nicole K Andeen, J Ashley Jefferson, Shreeram Akilesh, et al.
Page
of 53